Multicenter, randomized study comparing the efficacy and safety of two doses of thalidomide (100 mg/day versus 400 mg/day) in the treatment of subjects with refractory or relapsed multiple myeloma

Trial Profile

Multicenter, randomized study comparing the efficacy and safety of two doses of thalidomide (100 mg/day versus 400 mg/day) in the treatment of subjects with refractory or relapsed multiple myeloma

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 07 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top